Medical technology company Respiri has taken delivery of its first batch of Wheezo devices to monitor wheezing and breathing in asthma sufferers.
The devices, manufactured by miniaturised electronics manufacturer SRX Global, are the first of 500 Wheezos being delivered to prepare for full commercialisation of the product in the fourth quarter of 2020.
SRX Global operates from more than 23,000 square metres of facilities in Victoria and Malaysia.
Respiri said the delivery was a milestone in the development of its breath and asthma wheeze detection sensor.
The company said it was pleasing that 95 per cent of the units delivered by SRX passed compliance testing.
The units will be deployed in a patient and clinician experimental programme in the second quarter of 2020.
The programme will give clinicians full access to the Wheezo eHealth SaaS platform, providing important insights to underpin commercial sales.
Subscribe to our free @AuManufacturing newsletter here.